Redeye comments on Initiator Pharma’s announcement that the last patient has been dosed in the phase IIa proof-of-concept study of pudafensine in vulvodynia. $INIT redeye.se/research/1189606/i…

Redeye comments on Magle's announcement that it has submitted an application to Nasdaq Stockholm for the delisting of its shares from Nasdaq First North Growth Market, with 11 November requested as the last day of trading. $MAGLE redeye.se/research/1189553/m…

Redeye comments on AlzeCure's announcement that CEO Martin Jönsson is stepping down by mutual agreement with the Board. $ALZCUR redeye.se/research/1189550/a…

Redeye comments on the FDA approving Lucamzi, Xbrane’s Lucentis biosimilar, two days ahead of the 29 October BsUFA date. $XBRANE redeye.se/research/1189517/x…

Redeye comments on NextCell’s ProTrans-Young study, which missed its primary endpoint, with the preliminary two-year data in the older cohort not showing a widening treatment effect. $NXTCL redeye.se/research/1189135/n…

Redeye provides an update following Neem's Hill's Q3 2026 report. $NEEMSB redeye.se/research/1189320/n…

Redeye previews Oncopeptides’ Q3 report, due on 5 November. We discuss our assumptions and the importance of early signs of operating leverage. $ONCO redeye.se/research/1189368/o…

Redeye interviews NextCell’s CEO, Mathias Svahn, about the recently announced ProTrans-Young study results, financing and partnering opportunities and the next steps for the company. $NXTCL redeye.se/research/1189420/n…

Redeye provides an update following Safeture’s Q3 report, with ARR reaching SEK63.5m (+11% y/y) and NRR at 100%, while the loss of a legacy client caused a temporary uptick in churn. $SFTR redeye.se/research/1189285/s…

Redeye shares its preview of Camurus’ Q3 2026 results, due on 5 November. $CAMX redeye.se/research/1189339/c…

Ascelia Pharma trades below Redeye's Fair Value estimate of SEK 1 per share and has Market Edge scores of 3 for Value (Fairly Priced) and 1 for Momentum (Very Weak). We spoke with our analyst about what he found to be most unexpected in the FDA minutes, what the main share price catalysts over the next 12 months are, and other key topics. This is a premium article, included in our paid plans from SEK 99/month $ACE redeye.se/research/1189173/a…

VD Henrik Bunge berättar om ett kvartal med stark lönsamhet men en tillväxt som fortsatt ligger under ambitionsnivån. Vidare beskriver Bunge hur bolagets försäljningskanaler och produktkategorier har utvecklats samt vad som ligger bakom det goda momentumet i Tyskland och Danmark. Därtill resonerar Bunge kring drivkrafterna bakom den starka bruttomarginalen. Slutligen berättar Bunge om prioriteringarna i den nya affärsplanen från 2027. $BORG redeye.se/research/1189288/b…

Redeye comments on Argo’s announcement that its subsidiary, Poseidon Diving Systems, has received pilot orders from the U.S. Navy and two unnamed NATO special forces units, alongside a stated target of SEK150m in Poseidon revenue by 2029. $ARGO redeye.se/research/1189191/a…

Redeye comments on VEF’s Q3 2026 report and Brazil’s presidential election. $VEF redeye.se/research/1189208/v…

Redeye provides an update following Addnode’s Q3 beat, driven by DM and PM. Redeye raises its EBITA estimates, but lowers its Base Case to SEK99 (102) as a higher risk-free rate offsets them. $ANOD redeye.se/research/1187328/a…

Redeye updates its estimates and valuation following MedCap’s Q3 2026 report. Sales were in line with our estimate, while adjusted EBITA beat by c16% on a 20.9% margin. We nudge down our fair value to SEK600 (SEK620), mainly on a higher WACC. $MCAP redeye.se/research/1189176/m…

Moderna and Merck have now shown in phase 3 at ESMO that a cancer vaccine can reduce the risk of relapse, and Redeye has interviewed Mendus CEO Erik Manting about what this breakthrough means for the market and where vididencel fits in. $IMMU redeye.se/research/1189154/m…

Redeye has interviewed Ependion’s CEO, Jenny Sjödahl, who comments on the third quarter, in which Ependion posted strong growth while earnings reached a new all-time high, and shares her view on the market climate. $EPEN redeye.se/research/1189150/e…